1. What's new and not so new on the antimicrobial horizon?
G.L. French 
Clinical Microbiology and Infection 
Volume 14, Pages (December 2008)
DOI: /j x
Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

2. Fig. 1
Chemical structures of: ceftobiprole medocaril (formerly BAL5788; water-soluble prodrug for parenteral administration) and its microbiologically active compound, ceftobiprole (formerly BAL9141); doripenem (formerly S-4661), meropenem and imipenem; iclaprim (formerly AR-100); and trimethoprim.
aAdapted from: Schmitt-Hoffmann et al. [18]. bAdapted from: Jones et al. [17]. cAdapted from: Merrem IV Prescribing Information. dAdapted from: Primaxin IV Prescribing Information. eAdapted from: Schneider et al. [19].
Clinical Microbiology and Infection  , 19-29DOI: ( /j x)
Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

3. Fig. 2
Study design of STudy of Resistant Staphyloccocus aureus in Skin and Skin structure infections (STRAUSS) I trial (ceftobiprole phase 3 registration study). cSSSI, complicated skin and skin structure infection.
Adapted from: Noel et al. [24].
Clinical Microbiology and Infection  , 19-29DOI: ( /j x)
Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

4. Fig. 3
Results of STudy of Resistant Staphyloccocus aureus in Skin and Skin structure infections (STRAUSS) I trial (ceftobiprole phase 3 registration study), showing the distribution of pathogens overall, and according to genera and species.
Adapted from: Amsler et al., 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2006.
Clinical Microbiology and Infection  , 19-29DOI: ( /j x)
Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

5. Fig. 4
Study design of doripenem phase 3 registration study. IV, intravenous; PO, oral.
Adapted from: Malafaia et al., 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2006, Presentation No. L-1564b.
Clinical Microbiology and Infection  , 19-29DOI: ( /j x)
Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

6. Fig. 5
Study design of ASSIST I trial (iclaprim phase 3 registration study). cSSSI, complicated skin and skin structure infection; MRSA, methicillin-resistant Staphylococcus aureus; IV, intravenous; ITT, intention-to-treat.
Adapted from: Arpida press release ( (accessed 23 April 2008).
Clinical Microbiology and Infection  , 19-29DOI: ( /j x)
Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions